Biodesix receives key U.S. patent

BROOMFIELD – Biodesix Inc. in Broomfield received a patent that covers the bioscience firm’s first product, VeriStrat, which can be used by physicians to help guide therapy for patients with advanced lung cancer.

The United States Patent and Trademark office issued the patent for Biodesix’s serum-based method of identifying patients likely to benefit from several different therapies for cancer, including epidermal growth factor targeted therapy, drug therapies directed against the epidermal growth factor pathway and related molecular targets.

The patent also covers mass-spectrometry processes, algorithms and other important aspects of the company’s core technology, ProTS, the cornerstone of the company’s intellectual property portfolio.

SPONSORED CONTENT

How dispatchable resources enable the clean energy transition

Platte River must prepare for the retirement of 431 megawatts (MW) of dispatchable, coal-fired generation by the end of the decade and address more frequent extreme weather events that can bring dark calms (periods when there is no sun or wind).

“The granting of this patent recognizes our unique approach and innovation in this exciting area of molecular diagnostics,´ said David Brunel, chief executive of Biodesix.

The patent number is 7,736,905.